| 2020 | 2021 | 2022 | 2023 (projected) | Interest Expense | 3.05 M | 12.56 M | 2.56 M | 2.62 M | Gross Profit | 63.27 M | 103.34 M | 112.63 M | 97.57 M |
Ownership Breakdown
| Retail Investors10.92% | Institutions85.94% |
| Retail Investors | 10.92 | |
| Insiders | 3.14 | |
| Institutions | 85.94 |
Cardlytics (USA Stocks:CDLX) continues to rise
 | By Vlad Skutelnik | Macroaxis Story |
Cardlytics (NASDAQ: CDLX), a prominent player in the Communication Services sector and the Advertising Agencies industry, continues to maintain its upward momentum in the US stock market. Despite a challenging fiscal year ending in December, marked by a loss of $465.3 million from continuing operations and a profit margin of -1.64%, the company has managed to sustain its market position. With an enterprise value of $522.6 million, Cardlytics' resilience is noteworthy. The company, which operates domestically, reported a gross profit of $115.4 million on revenues of $294.9 million. However, the company's return on assets stands at -0.07, and it recorded a quarterly revenue growth of -0.05. Cardlytics, which employs 489 full-time employees, is currently under the analyst overall consensus of 'Sell', with five analysts providing estimates. The company's EPS estimate for the current year is -0.32, and it is expected to be -0.17 for the next quarter. Despite these challenges, Cardlytics' valuation hype value stands at 13.39, significantly higher than its real value of 9.03. The company's net interest income was a loss of $2.6 million, and it incurred an income tax expense of $1.4 million. Despite the negative EBITDA of $79.1 million, Cardlytics continues to demonstrate potential for growth and resilience in the market. As the company navigates through these financial challenges, investors and market watchers are keenly observing its performance and potential for recovery. Cardlytics' Cash and Equivalents Turnover is currently fairly stable compared to the previous year. In 2022, Cardlytics reported a Cash and Equivalents Turnover of 1.68. The company's Revenue to Assets ratio is projected to increase to 0.44 in 2023, while the Net Income Per Employee is expected to decrease to $953.1K in the same year. As conservative investors are showing increased interest in the media sector, Cardlytics could be a potential addition to your investment radar. We will examine whether it's still feasible for Cardlytics to reduce net losses this year. In this article, I will also discuss some key indicators that Cardlytics investors should consider in September.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Gabriel Shpitalnik
Cardlytics (NASDAQ: CDLX), a prominent player in the advertising industry, continues to demonstrate robust performance in the US stock market. The company, which operates in the media service category with a concentration in advertising, has an enterprise value of 522.6M and reported a revenue of 294.9M. Despite the current EPS estimate for the next year indicating a loss of 0.44, the company's stock has maintained an upward trajectory with a price change of 2.23 and a significant price percent change of 19.79. The trading volume for today stands at 2.9M, indicating a strong market interest in CDLX. With a total risk alpha of 0.8893 and a Sortino ratio of 0.1901, Cardlytics presents a viable investment opportunity for those willing to navigate the risks associated with the advertising industry.
Additional examination
Cardlytics, currently valued at $9.03 per share, appears overvalued given its modest future projections. The company holds a performance score of 17 on a scale of zero to a hundred. It has a Beta (market volatility) of 1.4202, indicating a relatively significant risk compared to the market. This suggests that as the market rises, Cardlytics is likely to outperform it. However, in the event of negative market returns, Cardlytics is likely to underperform. While it's crucial to consider Cardlytics' historical returns, it's equally important to be realistic about what can be achieved with its current equity trends. Our approach to predicting the future performance of any stock involves not only examining its past charts but also the overall business, including all fundamental and technical indicators. To determine whether Cardlytics' expected return of 1.55 will be sustainable in the future, we have identified twenty-one different technical indicators. These can assist you in verifying if the anticipated returns are sustainable. Utilize Cardlytics' standard deviation, maximum drawdown, and the relationship between the maximum drawdown and expected shortfall to analyze the company's future returns.The performance of Cardlytics in the marketplace will significantly impact your decision to invest in its stock. Revenue growth, profitability, competitive positioning, management quality, and industry trends can influence Cardlytics' stock prices. When investing in Cardlytics, there are several factors to consider and potential outcomes to expect. As a company performs well, its stock price may increase, allowing investors to benefit from price appreciation. However, Cardlytics Stock can experience significant price fluctuations due to market conditions, economic factors, industry trends, or company-specific news. This is why investing in stocks such as Cardlytics carries risks, including the potential for capital loss. Stock prices can decline, and investors may incur losses if they sell shares at a lower price than their initial investment.How important is Cardlytics's Liquidity
Cardlytics financial leverage refers to using borrowed capital as a funding source to finance Cardlytics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Cardlytics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Cardlytics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Cardlytics' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Cardlytics's total debt and its cash.
What do experts say about Cardlytics?
Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
Analysis ConsensusAn Additional Perspective On Cardlytics
Cardlytics holds a total of thirty-three million nine hundred eight thousand two hundred outstanding shares. The majority of Cardlytics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Cardlytics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Cardlytics. Please pay attention to any change in the institutional holdings of Cardlytics as this could imply that something significant has changed or about to change at the company. Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Cardlytics (NASDAQ: CDLX), a prominent player in the advertising agencies industry, continues to maintain its upward momentum in the US stock market. Despite a net income loss of $465.3M and an EBITDA of -$79.1M, the company's market capitalization stands at a robust $382.15M.The firm's shares are primarily owned by institutions, accounting for 85.94% of the total shares, while insiders hold 3.14%. Cardlytics' current liabilities are relatively low at $52.77M, compared to its net assets of $691.24M. However, the company's current ratio of 0.90X indicates a potential liquidity risk. The company's total debt is $235.26M, which is manageable considering its enterprise value of $522.6M. Despite a quarterly revenue growth of -0.05, the company's revenue per share is $8.835, which is promising. The company's beta of 1.8 indicates higher volatility compared to the market, which is reflected in its high probability of bankruptcy at 75.26%. However, with a risk-adjusted performance of 0.1261 and a market risk-adjusted performance of 1.02, Cardlytics is showing resilience in a challenging market environment. .
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Cardlytics. Please refer to our Terms of Use for any information regarding our disclosure principles.